Organisation paid for research Program year 2022 Source: CMS Open Payments

C1 Headlands LLC

Neither a doctor nor a teaching hospital

Research payments

$941,407

86 payments

Through program year 2022, C1 Headlands LLC is reported as receiving $941,407 in research payments, across 86 payments.

By program year

3 rows
Year Kind Amount Payments
2022 Research $398,041 31
2021 Research $458,207 35
2020 Research $85,158 20

Breakdown

Who paid Research payments · program years 2020–2022
  1. Pfizer Inc. $793,926 63 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $64,933 4 payments
  3. Gilead Sciences, Inc. $40,994 6 payments
  4. Organon LLC $34,785 4 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $5,269 5 payments
  6. Celgene Corporation $1,500 4 payments
Studies the money was for Research payments · program years 2020–2022
  1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $634,058 34 payments
  2. A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $159,868 29 payments
  3. POCC in NASH $64,933 4 payments
  4. 8415-8415-060-PN060-Extended Duration Study (Celanese + 2 years)-Contraception-SC-imp-Supplemental Registration-USA-LD-B $16,885 1 payment
  5. A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK-8415 Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger $15,400 2 payments
  6. A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease $12,893 1 payment
  7. Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease $12,893 1 payment
  8. Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease $7,500 1 payment
  9. Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease $3,457 1 payment
  10. Bay1002670 Endometriosis Dose finding EU & US JP CN $3,250 3 payments
What the money was spent on Research payments · program years 2020–2022
  1. Patient care $34,785 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record